TOP HEADLINES

Editor's Corner

  • VisualDx sees big future for mobile diagnostic tool

    Point-of-care diagnostics are picking up steam in the industry, with companies rolling out mobile platforms and smartphone apps that can quickly identify diseases. VisualDx is taking a different approach, offering a quick diagnostic tool that uses images rather than text to help physicians screen for certain conditions. Read more >>

Veracyte unveils $40M private placement to generate cash for R&D

Veracyte is selling $40 million of its common stock in a private placement to generate some cash for R&D, adding fuel to its engine as it inks new deals and looks to expand its portfolio.

Roche charges ahead with diagnostics R&D after sealing Foundation deal

Roche is not wasting any time after sealing its $1.2 billion deal for Foundation Medicine, charging full speed ahead with the companies' planned cancer R&D collaboration to generate growth in the coming year.

FDA, industry scrambling to clarify or design new regs covering lab-developed tests

Science is rapidly shaping the landscape of the diagnostics industry, from the research into genetics and new materials like graphene, to the regulatory science practiced at the FDA.

Color Genomics unveils $249 spit test for breast and ovarian cancer

California genetic testing firm Color Genomics launched its $249 spit test kit for breast and ovarian cancer, making its foray into a crowded BRCA market.

Cardinal Health pays feds $26M to settle charges of monopolizing molecular imaging agent market

The federal antitrust watchdog came down hard on Dublin, OH's Cardinal Health for allegedly monopolizing the market for certain radiation-emitting diagnostics for heart disease. Cardinal Health agreed to pay a $26.8 million fine to the Federal Trade Commission to compensate injured patients, in what is the second largest settlement the commission has obtained in an antitrust case.

MORE NEWS

From Our Sister Sites

FiercePharma Manufacturing

It has taken more than a year to get its manufacturing problems, and lozenges, back into shape and shipped, but GlaxoSmithKline says some Nicorette Lozenges are back on retailer shelves. That is particularly good news for those former smokers who have substituted a Nicorette habit for a smoking one.

FiercePharma

Wednesday's a big day for Amgen, whose dual-acting cancer vaccine/viral therapy is coming up for review by an FDA panel of experts.